News
-
Press
Jan 23, 2023
ThinkCyte broadens Advisory Board with the appointments of Dr. Diether Recktenwald, Ph.D. and Dr. Bo Saxberg, M.D. Ph.D.
-
Press
Dec 26, 2022
ThinkCyte and Axcelead DDP collaborate to advance novel phenotypic drug screening methods
-
Press
Dec 13, 2022
PhoreMost and ThinkCyte collaborate to advance AI-based drug discovery
-
Press
Dec 6, 2022
Vision Care Group and ThinkCyte Announce Research Alliance in Advanced Cell Therapy
-
Press
Jul 21, 2022
ThinkCyte announces Premier Early Access Program for its new label-free cell characterization and sorting system
-
Press
Jul 11, 2022
ThinkCyte shares applications of Ghost Cytometry with industrial and academic thought leaders
-
Press
Jun 23, 2022
ThinkCyte Establishes Presence in the Bay Area and Strengthens Senior Management Team With Industry Veteran
-
Press
Dec 21, 2021
ThinkCyte’s novel label-free in-silico ghost cytometry published in eLife
-
Press
May 19, 2021
ThinkCyte Secures $26 Million in Series B Financing
-
Press
May 12, 2021
Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance
-
Press
Aug 24, 2020
ThinkCyte Awarded NEDO PCA Grant to Advance Label-free Cell Sorting Technology for Cell Therapy
-
Press
Jul 9, 2020
ThinkCyte and National Cancer Center Japan Jointly Awarded AMED Grant for Isolation of Circulating Tumor Cells
-
Press
Jul 1, 2020
Hitachi and ThinkCyte Announce Collaboration to Develop an AI-driven Cell Analysis and Sorting System
-
Press
May 29, 2020
ThinkCyte Completes $15 Million Series A Financing
-
Press
Jun 15, 2018
ThinkCyte Publishes Paper on “Ghost Cytometry” Method in Science
-
Press
Jun 15, 2018
ThinkCyte Completes Seed Financing